Scientists talked about the role of a bacterial molecule in intestinal repair
A molecule produced by some intestinal bacteria has helped repair damaged mucosa in mice and increased the survival rate of drosophila with intestinal damage. In experiments with human cells, this substance served as a source of NAD+, a coenzyme involved in energy metabolism. About how scientists traced the path of the bacterial molecule and what the tests of patients with Crohn's disease and ulcerative colitis showed is in the Izvestia article.
How the intestine repairs the mucous membrane
The cells lining the colon are normally renewed in about a week. New cells are formed from stem cells that are located in the recesses of the mucous membrane. Constant renewal maintains the barrier between the contents of the intestine and the rest of the tissues. When the mucosa is damaged, cell division helps restore its integrity.
In Crohn's disease and ulcerative colitis, the mucosa can be damaged due to chronic inflammation. The authors tested whether it is possible to support its recovery with the help of a substance that the cell uses to synthesize NAD+. It is a form of nicotinamide adenine dinucleotide, a coenzyme that participates in energy production reactions and is necessary for the operation of a number of DNA repair enzymes.
How does a bacterial molecule differ from a human one?
The researchers named the discovered compound amide N-methylnicotinamide, or N-MNA. It has the same set of atoms as 1-methylnicotinamide, which human cells form when processing excess nicotinamide. The compounds differ in the position of the methyl group, a small fragment of the molecule.
"A small difference makes it possible to convert a bacterial compound into NAD," explained Xiaoyang Su, associate professor of medicine at Rutgers University.
One of the most active producers of N-MNA among the studied bacteria turned out to be the Lacticaseibacillus rhamnosus GG (LGG) strain, which is used in probiotics. When this strain was colonized in the intestines of mice grown without their own microbiota, there was more N-MNA in their stool samples.
How cells use N-MNA
To trace the fate of the substance, scientists labeled it with deuterium, a stable isotope of hydrogen. N-MNA was then added to the culture of human colon epithelial cells. Both the labeled substance and the NAD, into which its label passed, were found inside the cells. After a day, the basic labeled form accounted for 21.8% of the total NAD in the cells.
Labeled NAD has also been found in other experiments, in cellular models of the liver and kidneys, as well as in neurons derived from human stem cells. NAD+ is also being studied in connection with aging, as its level in some tissues may decrease with age. The authors of the review in Nature Metabolism note that there is still little data on such changes in humans, and trials of known NAD+ precursors have shown limited clinical effect.
What experiments on mice and fruit flies have shown
Mice with experimental colitis were injected with N-MNA during the development of inflammation and during the recovery period. In the first three days, the weight of the animals treated with the substance decreased by about 5%. In the control group, weight loss reached about 20% of the initial weight. Weight dynamics was compared in groups of four mice. The animals treated with N-MNA also showed less mucosal damage and lower levels of lipocalin-2, a marker of inflammation.
In another experiment, scientists tagged intestinal stem cells to then discover their descendants. After the recovery period, approximately eight times more sites with descendants of these cells were found on slices of the terminal colon of mice treated with N-MNA than in the control group.
In fruit flies with damaged intestines, 77.7% of the N-MNA-treated insects and 42.6% in the comparison group survived by the seventh day. There were 124 flies in each group. In a separate experiment, the protective effect of the substance weakened when the production of the enzyme SIRT1 was reduced in the intestinal stem cells of flies. NAD+ is required for this enzyme to work.
What was found in the patient samples
The researchers examined stool samples from 29 people with Crohn's disease, 25 with ulcerative colitis, and 20 healthy volunteers. The samples were collected at a clinic in Rzeszow, Poland. In the group with Crohn's disease, the N-MNA content was lower on average than in healthy participants.
"Patients with low levels of this metabolite had higher inflammatory activity," said Nan Gao, professor of pharmacology, physiology and neurobiology at Rutgers University.
In both diagnoses, a low N-MNA content was combined with a higher level of fecal calprotectin, a protein used to assess the activity of inflammation. Patients with ulcerative colitis and a lower N-MNA content also had a less diverse microbiota. To find out if these changes precede an exacerbation, you need to trace them over time.
What can this change in treatment?
Mucosal healing is one of the goals of Crohn's disease and ulcerative colitis treatment. It is evaluated during endoscopy, since the inflammation can persist even after the symptoms have subsided. The participation of patients in the work was limited to the analysis of samples. In clinical trials, it has yet to be verified whether the use of N-MNA is safe and whether the substance helps to restore the mucous membrane in humans.
In experiments on mice, scientists injected the finished substance. To evaluate the effect of probiotics, it is necessary to find out how much N-MNA bacteria produce in the human intestine and whether this will affect the content of NAD+ in cells. The American Gastroenterological Association recommends the use of probiotics for the treatment of Crohn's disease and ulcerative colitis only in clinical trials.
Переведено сервисом «Яндекс Переводчик»